Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients

Stefano De Servi, Nuccia Morici, Enrico Boschetti, Roberta Rossini, Paola Martina, Giuseppe Musumeci, Maurizio D'Urbano, Ludovico Lazzari, Carlo La Vecchia, Michele Senni, Silvio Klugmann, Stefano Savonitto

Research output: Contribution to journalArticle

Abstract

Intravenous administration of a short acting glycoprotein IIb/IIIa inhibitor has been proposed as a bridge to surgery in patients on dual antiplatelet treatment, but data in comparison with other treatment options are not available. We conducted a retrospective analysis of consecutive patients who underwent un-deferrable, non-emergency surgery after coronary stenting. The bridge therapy was performed after discontinuation of the oral P2Y12 inhibitor by using i.v. tirofiban infusion. Net Adverse Clinical Events (NACE) was the primary outcome.We analyzed 314 consecutive patients: the bridge strategy was performed in 87 patients, whereas 227 were treated with other treatment options and represent the control group. Thirty-day NACE occurred in 8% of patients in the bridge group and in 22.5% in the control group (p.

Original languageEnglish
JournalVascular Pharmacology
DOIs
Publication statusAccepted/In press - Aug 31 2015

Keywords

  • ADP receptors
  • Coronary syndrome
  • Platelet glycoproteins

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Physiology

Fingerprint Dive into the research topics of 'Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients'. Together they form a unique fingerprint.

Cite this